5,550 Shares in argenex SE $ARGX Bought by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of argenex SE (NASDAQ:ARGX) in the 4th quarter, HoldingsChannel reports. The institutional investor purchased 5,550 shares of the company’s stock, valued at approximately $4,662,000.

Several other hedge funds have also recently modified their holdings of the stock. Capital World Investors lifted its holdings in shares of argenex by 0.4% during the third quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after purchasing an additional 8,422 shares during the period. M&T Bank Corp lifted its holdings in shares of argenex by 20,977.7% during the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares during the period. Wellington Management Group LLP lifted its holdings in shares of argenex by 80.1% during the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after purchasing an additional 324,653 shares during the period. Bank of America Corp DE lifted its holdings in shares of argenex by 1.9% during the third quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock worth $252,525,000 after purchasing an additional 6,259 shares during the period. Finally, Two Sigma Investments LP lifted its holdings in shares of argenex by 570.3% during the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after purchasing an additional 250,278 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on ARGX shares. Citizens Jmp raised their target price on argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a report on Friday, February 27th. Wells Fargo & Company raised their target price on argenex from $1,247.00 to $1,260.00 and gave the company an “overweight” rating in a report on Friday. Glj Research raised argenex to a “strong-buy” rating in a report on Friday, April 3rd. HC Wainwright raised their target price on argenex from $915.00 to $940.00 and gave the company a “buy” rating in a report on Friday, February 27th. Finally, Oppenheimer reduced their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a report on Thursday, April 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,017.78.

argenex Stock Performance

argenex stock opened at $813.28 on Tuesday. argenex SE has a one year low of $510.05 and a one year high of $934.62. The business has a fifty day moving average of $755.99 and a two-hundred day moving average of $816.91. The company has a market cap of $50.58 billion, a P/E ratio of 36.21, a price-to-earnings-growth ratio of 1.31 and a beta of 0.46.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%.The business had revenue of $1.31 billion during the quarter. Sell-side analysts predict that argenex SE will post 23.96 EPS for the current year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.